Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus Nucleos(t)ide Analogues in Chronic Hepatitis B
NCT05256823Phase 2Unknown
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib in Chronic Hepatitis B (CHB) (2 arms). Primary endpoints: The rate of HBsAg loss and The reduction of HBsAg. Status: unknown.
02
Drugs
celecoxib
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05256823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256823.